Cargando…

Timely Resolution of SARS-CoV-2-Related Multi-System Inflammatory Syndrome in Children

Background: Multisystem inflammatory syndrome in children (MIS-C) is a severe, postinfectious manifestation of coronavirus disease 2019 (COVID-19) in the pediatric population. The disease is manifested by hyperinflammation and can result in cardiac dysfunction, coronary changes, and end-organ damage...

Descripción completa

Detalles Bibliográficos
Autores principales: Reiff, Daniel D., Cron, Randy Q.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9866445/
https://www.ncbi.nlm.nih.gov/pubmed/36680134
http://dx.doi.org/10.3390/v15010094
_version_ 1784876093349560320
author Reiff, Daniel D.
Cron, Randy Q.
author_facet Reiff, Daniel D.
Cron, Randy Q.
author_sort Reiff, Daniel D.
collection PubMed
description Background: Multisystem inflammatory syndrome in children (MIS-C) is a severe, postinfectious manifestation of coronavirus disease 2019 (COVID-19) in the pediatric population. The disease is manifested by hyperinflammation and can result in cardiac dysfunction, coronary changes, and end-organ damage. Adequate timely treatment can prevent poor outcomes in the short term, but long-term data is lacking. Methods: A large single center MIS-C cohort was followed longitudinally after treatment with intravenous immunoglobulin (IVIG) ± glucocorticoids to determine the natural history of the disease and to describe improvement in laboratory markers and cardiac outcomes. Patient were stratified by disease severity and compared. Results: 137 patients were identified with demographics similar to previously described cohorts. Regardless of disease severity, when adequately treated, initial lab abnormalities rapidly improved by the 6–8 month follow-up period, with some resolved in as little as 1–2 weeks. Similarly, cardiac abnormalities improved quickly after treatment; all abnormalities resolved in this cohort by 1–2 months post-hospitalization. Conclusions: Although MIS-C is a serious sequela of COVID-19, when identified quickly and treated aggressively, laboratory abnormalities, coronary dilatation, and systolic dysfunction rapidly improve with minimal long-term morbidity or mortality.
format Online
Article
Text
id pubmed-9866445
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-98664452023-01-22 Timely Resolution of SARS-CoV-2-Related Multi-System Inflammatory Syndrome in Children Reiff, Daniel D. Cron, Randy Q. Viruses Article Background: Multisystem inflammatory syndrome in children (MIS-C) is a severe, postinfectious manifestation of coronavirus disease 2019 (COVID-19) in the pediatric population. The disease is manifested by hyperinflammation and can result in cardiac dysfunction, coronary changes, and end-organ damage. Adequate timely treatment can prevent poor outcomes in the short term, but long-term data is lacking. Methods: A large single center MIS-C cohort was followed longitudinally after treatment with intravenous immunoglobulin (IVIG) ± glucocorticoids to determine the natural history of the disease and to describe improvement in laboratory markers and cardiac outcomes. Patient were stratified by disease severity and compared. Results: 137 patients were identified with demographics similar to previously described cohorts. Regardless of disease severity, when adequately treated, initial lab abnormalities rapidly improved by the 6–8 month follow-up period, with some resolved in as little as 1–2 weeks. Similarly, cardiac abnormalities improved quickly after treatment; all abnormalities resolved in this cohort by 1–2 months post-hospitalization. Conclusions: Although MIS-C is a serious sequela of COVID-19, when identified quickly and treated aggressively, laboratory abnormalities, coronary dilatation, and systolic dysfunction rapidly improve with minimal long-term morbidity or mortality. MDPI 2022-12-29 /pmc/articles/PMC9866445/ /pubmed/36680134 http://dx.doi.org/10.3390/v15010094 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Reiff, Daniel D.
Cron, Randy Q.
Timely Resolution of SARS-CoV-2-Related Multi-System Inflammatory Syndrome in Children
title Timely Resolution of SARS-CoV-2-Related Multi-System Inflammatory Syndrome in Children
title_full Timely Resolution of SARS-CoV-2-Related Multi-System Inflammatory Syndrome in Children
title_fullStr Timely Resolution of SARS-CoV-2-Related Multi-System Inflammatory Syndrome in Children
title_full_unstemmed Timely Resolution of SARS-CoV-2-Related Multi-System Inflammatory Syndrome in Children
title_short Timely Resolution of SARS-CoV-2-Related Multi-System Inflammatory Syndrome in Children
title_sort timely resolution of sars-cov-2-related multi-system inflammatory syndrome in children
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9866445/
https://www.ncbi.nlm.nih.gov/pubmed/36680134
http://dx.doi.org/10.3390/v15010094
work_keys_str_mv AT reiffdanield timelyresolutionofsarscov2relatedmultisysteminflammatorysyndromeinchildren
AT cronrandyq timelyresolutionofsarscov2relatedmultisysteminflammatorysyndromeinchildren